急诊心衰死亡风险分级(EHMRG)的前瞻性验证
本研究为多中心前瞻性验证研究,纳入1983例急诊急性心衰患者,验证EHMRG7和EHMRG30-ST模型对7天和30天死亡的预测能力。EHMRG7的c统计量为0.81,优于医生估计的0.71(P=0.022),联合医生估计后c统计量为0.82。EHMRG30-ST的c统计量为0.77。模型能识别低风险患者,可能指导临床决策。
要点
- EHMRG7对7天死亡的区分度优于医生估计(c统计量0.81 vs 0.71)。
- EHMRG7联合医生估计未显著提高区分度(P=0.242)。
- EHMRG30-ST对30天死亡的c统计量为0.77。
核心结论
- EHMRG模型可同时预测7天和30天死亡,识别低风险急性心衰患者。
- 与医生估计相比,多变量模型能更好地预测7天死亡,可能指导临床决策。
研究设计与样本
- 多中心前瞻性验证研究,在9家医院纳入1983例急诊急性心衰患者。
- 在获知模型预测前调查医生对7天死亡风险的估计,并与EHMRG7比较区分度和净重分类改善。
- 前瞻性检验EHMRG30-ST模型的区分度,该模型包含EHMRG7所有组分及12导联心电图ST段压低。
主要发现
- 7天死亡率在极低、低、中、高、极高风险5组分别为0%、0%、0.6%、1.9%、3.9%。
- 30天死亡率在对应5组分别为0%、1.9%、3.9%、5.9%、14.3%。
- 医生估计7天死亡的c统计量为0.71(95%CI 0.64-0.78),EHMRG7为0.81(95%CI 0.75-0.87;P=0.022 vs 医生估计)。
- EHMRG7联合医生估计的c统计量为0.82(95%CI 0.76-0.88;P=0.003 vs 医生估计),较EHMRG7单独提高0.014(95%CI -0.009-0.037;P=0.242)。
- EHMRG30-ST单独c统计量为0.77(95%CI 0.73-0.81),联合医生估计提高至0.78(95%CI 0.73-0.82;P=0.187)。
临床怎么用
- 急诊急性心衰患者可用EHMRG7评估7天死亡风险,辅助入院或早期出院决策。
- EHMRG30-ST可同时评估30天死亡风险,识别低风险患者。
- 模型预测可补充医生临床估计,尤其优化7天死亡风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improved risk stratification of acute heart failure in the emergency department may inform physicians' decisions regarding patient admission or early discharge disposition. We aimed to validate the previously-derived Emergency Heart failure Mortality Risk Grade for 7-day (EHMRG7) and 30-day (EHMRG30-ST) mortality. METHODS: We conducted a multicenter, prospective validation study of patients with acute heart failure at 9 hospitals. We surveyed physicians for their estimates of 7-day mortality risk, obtained for each patient before knowledge of the model predictions, and compared these with EHMRG7 for discrimination and net reclassification improvement. We also prospectively examined discrimination of the EHMRG30-ST model, which incorporates all components of EHMRG7 as well as the presence of ST-depression on the 12-lead ECG. RESULTS: We recruited 1983 patients seeking emergency department care for acute heart failure. Mortality rates at 7 days in the 5 risk groups (very low, low, intermediate, high, and very high risk) were 0%, 0%, 0.6%, 1.9%, and 3.9%, respectively. At 30 days, the corresponding mortality rates were 0%, 1.9%, 3.9%, 5.9%, and 14.3%. Compared with physician-estimated risk of 7-day mortality (PER7; c-statistic, 0.71; 95% CI, 0.64-0.78) there was improved discrimination with EHMRG7 (c-statistic, 0.81; 95% CI, 0.75-0.87; P=0.022 versus PER7) and with EHMRG7 combined with physicians' estimates (c-statistic, 0.82; 95% CI, 0.76-0.88; P=0.003 versus PER7). Model discrimination increased nonsignificantly by 0.014 (95% CI, -0.009-0.037) when physicians' estimates combined with EHMRG7 were compared with EHMRG7 alone ( P=0.242). The c-statistic for EHMRG30-ST alone was 0.77 (95% CI, 0.73-0.81) and 30-day model discrimination increased nonsignificantly by addition of physician-estimated risk to 0.78 (95% CI, 0.73-0.82; P=0.187). Net reclassification improvement with EHMRG7 was 0.763 (95% CI, 0.465-1.062) when assessed continuously and 0.820 (0.560-1.080) using risk categories compared with PER7. CONCLUSIONS: A clinical model allowing simultaneous prediction of mortality at both 7 and 30 days identified acute heart failure patients with a low risk of events. Compared with physicians' estimates, our multivariable model was better able to predict 7-day mortality and may guide clinical decisions. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02634762.
引用
- Lee DS, Lee JS, Schull MJ, et al. Prospective Validation of the Emergency Heart Failure Mortality Risk Grade for Acute Heart Failure. Circulation. 2019. PMID: 30586748. doi:10.1161/CIRCULATIONAHA.118.035509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。